Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 211 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: STAR Clear all
Active, not recruiting Phase 3 Interventional Results available

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

NCT02166463
View directory record Official record
Conditions
Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Childhood Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Interventions
Bleomycin Sulfate, Brentuximab Vedotin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Methylprednisolone, Pharmacological Study, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Vincristine Sulfate
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 22 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
182
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 140 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 3, 2026, 5:27 AM EDT
Withdrawn Not applicable Interventional

Computerized Cognitive Training for Patients With Epilepsy

NCT03644082
View directory record Official record
Conditions
Epilepsy
Interventions
Luminosity Trial Memory Match, Luminosity Trial Memory Matrix, Luminosity Trial Famliar Faces, Luminosity Trial Brain Shift, Luminosity Trial Star Search, Luminosity Trial Word Bubbles, Luminosity Trial Color Match, Luminosity Trial Ebb and Flow, Luminosity TrialChalk Board Challenge, Luminosiuty Follow that Frog, Luminosity Train of Thought
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Sep 3, 2026, 5:27 AM EDT
Completed Phase 2 Interventional

Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)

NCT00993707
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
CTX-100 (formerly ETX-100) (hyaluronic acid)
Drug
Lead sponsor
Turino, Gerard, M.D.
Individual
Eligibility
40 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Sep 3, 2026, 5:27 AM EDT
Completed Not applicable Interventional

Strategies to Accommodate Reading (STAR)

NCT03312270
View directory record Official record
Conditions
Aphasia
Interventions
Multimodality information comprehension
Behavioral
Lead sponsor
Miami University
Other
Eligibility
19 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Oxford, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 3, 2026, 5:27 AM EDT
Withdrawn Phase 1 Interventional

Stem Cell Therapy as Adjunct to Revascularization

NCT00463853
View directory record Official record
Conditions
Coronary Arteriosclerosis, Coronary Artery Bypass Graft, Myocardial Revascularization
Interventions
Autologous stem cell therapy, CABG, CMRI
Procedure · Radiation
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 3, 2026, 5:27 AM EDT
Active, not recruiting Phase 2 Interventional

Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

NCT04068753
View directory record Official record
Conditions
Recurrent Cervix Cancer, Progressive Cervix Cancer
Interventions
Niraparib, dostarlimab
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 3, 2026, 5:27 AM EDT
Active, not recruiting Phase 3 Interventional

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

NCT05881408
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
delandistrogene moxeparvovec, placebo
Genetic
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
Male only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 3, 2026, 5:27 AM EDT
Completed Phase 2 Interventional

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

NCT03489629
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Trimethoprim Sulfamethoxazole (TMP/SMX), Minocycline, Mupirocin, Chlorhexidine Gluconate, Environmental Decontamination
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
2 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 3, 2026, 5:27 AM EDT
Completed No phase listed Observational

Blood Culture Improvement Guidelines and Diagnostic Stewardship for Antibiotic Reduction in Critically Ill Children

NCT03441126
View directory record Official record
Conditions
Sepsis, Bacteremia
Interventions
Multicenter Quality Improvement program
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
St Louis, Missouri • Cleveland, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 3, 2026, 5:27 AM EDT
Completed Not applicable Interventional

Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients

NCT00295139
View directory record Official record
Conditions
Schizophrenia, Mood Disorders, Substance Dependence
Interventions
Behavioral Treatment for Substance Abuse in SPMI (BTSAS), Supportive Treatment in Addiction Recovery (STAR), Critical Time Intervention (CTI)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Sep 3, 2026, 5:27 AM EDT
Completed No phase listed Observational

Post-Approval Study to Investigate the Long Term (8 Year) Survivorship of STAR Ankle Among Continued Access Study Patients

NCT01288586
View directory record Official record
Conditions
Primary Arthrosis
Interventions
Scandinavian Total Ankle Replacement System (STAR Ankle)
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
5
States / cities
Oakland, California • Temple Terrace, Florida • Boise, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 3, 2026, 5:27 AM EDT
Terminated Not applicable Interventional

Serial Third Trimester Abdominal Circumference and Amniotic Fluid Measurements Versus Routine Care

NCT03857659
View directory record Official record
Conditions
Fetal Growth Abnormality, Amniotic Fluid; Disorder
Interventions
Point-of-care ultrasound (POC-US), Routine antenatal care, Formal ultrasound
Diagnostic Test
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 3, 2026, 5:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Star Matrix vs Autogenous Graft for Gingival Augmentation: Split-Mouth RCT

NCT07440303
View directory record Official record
Conditions
Lack of Keratinized Gingiva, Mucogingival Deformity - Insufficient Keratinized Tissue
Interventions
Starmatrix collagen membrane, Autogenous gingival graft
Device · Other
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
20 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 3, 2026, 5:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema

NCT05695248
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Navenibart
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 3, 2026, 5:27 AM EDT
Recruiting Not applicable Interventional

Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF

NCT05934565
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Heart Failure
Interventions
Mindful Steps
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 3, 2026, 5:27 AM EDT
Not yet recruiting Not applicable Interventional

Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors

NCT07793994
View directory record Official record
Conditions
CNS Tumor, Solid Tumor, Relapsed Cancer, Refractory Cancer, Pediatric Cancer
Interventions
Bulk RNA Sequencing, Immunohistochemistry (IHC)
Diagnostic Test
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 30 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 3, 2026, 5:27 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

BrighT STAR LIBRA: Leveraging Implementation Science for Blood Culture Reduction Approaches

NCT06187662
View directory record Official record
Conditions
Blood Culture Rates, Antibiotic Stewardship, Implementation Science
Interventions
Checklist, Targeted Messaging
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Wilmington, Delaware + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 3, 2026, 5:27 AM EDT
Completed Phase 1 Interventional Results available

Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)

NCT00203203
View directory record Official record
Conditions
Ischemic Cardiomyopathy
Interventions
Intramyocardial Injection of stem cells via NOGA Mapping, Control, then Stem Cell Therapy
Device · Other
Lead sponsor
Texas Heart Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Sep 3, 2026, 5:27 AM EDT
Active, not recruiting Phase 3 Interventional

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT03007147
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
184
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 5:27 AM EDT
Completed Not applicable Interventional

Internet-based System for Cancer Patients to Self-report Toxicity

NCT00578006
View directory record Official record
Conditions
Cervical Cancer, Lung Cancer, Prostate Cancer, Vaginal Cancer, Ovarian Cancer, Breast Cancer, Bladder Cancer
Interventions
Questioners, STAR website
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 3, 2026, 5:27 AM EDT
Active, not recruiting Not applicable Interventional

LASIK iDesign vs SMILE

NCT07126756
View directory record Official record
Conditions
Myopia, Astigmatism
Interventions
STAR S4 IR Excimer Laser System, VisuMax 400 Surgical Laser
Device
Lead sponsor
59th Medical Wing
Federal
Eligibility
21 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 3, 2026, 5:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)

NCT05906953
View directory record Official record
Conditions
Leber Congenital Amaurosis, Inherited Retinal Diseases Caused by RPE65 Mutations
Interventions
HG004
Drug
Lead sponsor
HuidaGene Therapeutics Co., Ltd.
Industry
Eligibility
6 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 3, 2026, 5:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stress & Resilience Study

NCT06063174
View directory record Official record
Conditions
Stress, Stress, Psychological, Stress, Physiological, Stress, Emotional, Stress Reaction
Interventions
Education Program, Think Well Program, Be Well Program, Eat Well Program, Sleep Well Program, Move Well Program
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
712 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 3, 2026, 5:27 AM EDT
Completed Not applicable Interventional

Exercise in Adults with Post-Acute Sequelae of SARS-CoV-2 (COVID-19) Infection Study

NCT05218174
View directory record Official record
Conditions
COVID-19
Interventions
Exercise Prescription
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Frisco, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 3, 2026, 5:27 AM EDT